ANI Pharmaceuticals Inc (ANIP)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at ANI Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 79.20 $ — 45% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 40.8% passed
- More than 10% revenue growth is expected for the coming year 11.3% passed
- Share count grows by less than 3% a year 9.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 60.9% passed
- Gross margin at 40% or higher and without meaningful erosion 51.0% failed
- Goodwill from acquisitions does not grow faster than revenue 4.3% passed
- Net debt below twice EBITDA 0.2 x EBITDA passed
- Operating cash flow covers the profits of the last three years 290 m passed
- Return on capital at 15% or higher, or up versus two years ago 7.0% passed
- Insiders hold at least 10% or are net buyers 5.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 38.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9.42 | 9.19 – 9.68 | 1,122 | 19.4% | 8 |
| 12/31/2027 | 10.76 | 9.48 – 13.06 | 1,242 | 14.2% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.67 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.53 | -979.40 | 191 | 44.80 | -5.40 | 16 | 13 |
| 2025: Q1 | 0.78 | -16.60 | 197 | 43.40 | 8.00 | 35 | 15 |
| 2025: Q2 | 0.42 | – | 211 | 53.10 | 4.00 | 76 | 69 |
| 2025: Q3 | 1.14 | – | 228 | 53.60 | 10.60 | 44 | 38 |
| 2025: Q4 | 1.29 | – | 247 | 29.60 | 11.10 | 30 | 7 |
| 2026: Q1 | 1.37 | 75.00 | 238 | 20.50 | 12.40 | 58 | 47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 129 | 20 | 4 | 0.34 | 27 | 170 | 323 |
| 2017 | 177 | 28 | -1 | -0.09 | 39 | 175 | 412 |
| 2018 | 202 | 35 | 15 | 1.32 | 67 | 197 | 431 |
| 2019 | 207 | 16 | 6 | 0.51 | 46 | 213 | 457 |
| 2020 | 208 | -16 | -23 | -1.88 | 15 | 196 | 461 |
| 2021 | 216 | -40 | -43 | -3.38 | 3 | 359 | 772 |
| 2022 | 316 | -35 | -48 | -2.95 | -31 | 339 | 760 |
| 2023 | 487 | 47 | 19 | 1.03 | 119 | 458 | 904 |
| 2024 | 614 | 1 | -19 | -0.96 | 64 | 429 | 1,284 |
| 2025 | 883 | 81 | 78 | 3.69 | 185 | 541 | 1,440 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
ANI Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen, entwickelt, fertigt und vermarktet Marken- und Generika-Pharmaprodukte in den USA und international.
| Employees | 970 |
|---|---|
| Headquarters | Baudette, MN |
| Address | 210 Main Street West, 56623 Baudette, United States |
| Phone | 218 634 3500 |
| Website | anipharmaceuticals.com |
| IPO Date | 5. May 2000 |
| ISIN | US00182C1036 |
| Stock Split | 1:6 on 07/18/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Nikhil Lalwani | President, CEO & Director | 1978 |
| Stephen P. Carey | Senior VP of Finance & CFO | 1971 |
| Meredith W. Cook J.D. | Senior VP, General Counsel & Corporate Secretary | 1974 |
| Christopher K. Mutz | Senior VP & Head of Rare Disease | 1972 |
| Ori Gutwerg | Senior Vice President of Generics | 1975 |
| Muthusamy Shanmugam MS R.Ph. | Head of R&D, COO of New Jersey Operations & Director | 1968 |
| Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease | – |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1976 |
| Krista L. Davis | Senior VP & Chief Human Resources Officer | 1973 |
| Mary Pao M.D., Ph.D. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Carey Stephen P. | SVP & CFO | Sell | 2,850 | 81.36 | 231,876 |
| 18. Jul 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Other | 2,466 | 79.20 | 195,307 |
| 13. Jul 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | 81.84 | 40,920 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.